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There are very few studies regarding IMRT (Intensity Modulated Radiation Therapy) and the treatment of vulvar cancer. Therefore, we
will present our experience on IMRT treatment in adjuvant vulvar cancer, at our Department.
RESULTS
This work is based on a retrospective analysis of vulvar cancer treated with surgery and adjuvant IMRT between January 2009 and
February 2012.
All patients were treated with IMRT (sliding window), in a Clinac 2100CD (linear accelarator), with photon energy 6MV. For dosimetry,
the inversed planning system was used. It was evaluated the Planning Target Volume (PTV) coverage, the dose's homogeneity
distribution and the dose tolerance of the organs at risk – rectum (V40), bladder (V40), small bowel (V35) and bone marrow (V20).
The acute toxicity (intestinal, genitourinary and skin) was evaluated according to the Radiation Therapy Organization Group criteria.
CONCLUSIONS: IMRT seems to be a promising treatment in vulvar cancer. IMRT planning has a proper PTV coverage with considerable sparing of organs at risk and is well tolerated by patients.
We also achieve with IMRT a low loco-regional relapse, as mentioned in literature. 
Treatment Response
50%  patients alive at the present analysis
30% patients had loco-regional relapse
1 patient had distant metastasis
30 patients
AGE:  32  to  88 years  (median: 75)
HISTOLOGY:  Squamous cells carcinoma 
ALL COMPLETED TREATMENT
MEAN DOSE:  62.32Gy (50-66Gy)
FOLLOW-UP:  13 to 50 months




Small bowel 23.85 Gy
Bone marrow 22.27 Gy
OAR AVERAGE DOSE
V40 Rectum 28.40 Gy
V40 Bladder 26.09 Gy
V35 Small bowel 26.40 Gy
V20 Bone marrow 48.59 Gy
Table 1 and 2: OAR average doses
Fig. 3 and 4: IMRT Dosimetry 
Fig. 1 and 2: PTV coverage - 95% isodoses curve
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Graphic  3: Toxicities 
2.12% cases: PTV <95% of the prescribed dose
1 case:  PTV >107% of the prescribed dose
